LAMA Therapies Carry Lesser Risk of Flares and Side Effects Than LABA in People with Stable COPD, Study Says
News
LAMA (long-acting muscarinic antagonist) treatments may be more beneficial to people with stable chronic obstructive pulmonary disease (COPD) than those with LABA (long-acting beta2-agonist), especially in patients at risk of frequent exacerbations, ... Read more